CRISPR THERAPEUTICS AG (CRSP) Total liabilities 2016–2025
CRISPR THERAPEUTICS AG (CRSP) total liabilities at each fiscal year-end, per SEC filings.
$343.4MFY2025 · since FY2016: $112.1M → $343.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $343.4M | +10.8% |
| FY2024 | $310.0M | -10.6% |
| FY2023 | $346.8M | -5.7% |
| FY2022 | $367.6M | +4.3% |
| FY2021 | $352.4M | +115.2% |
| FY2020 | $163.7M | +28.6% |
| FY2019 | $127.3M | +31.5% |
| FY2018 | $96.8M | +15.9% |
| FY2017 | $83.5M | -25.5% |
| FY2016 | $112.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating marginCRSP Operating cash flowCRSP Free cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Shareholders’ equityCRSP overview →